Our results demonstrate that noninvasive molecular imaging of EGFR may open the door to guiding the selection and monitoring of anti-EGFR targeted therapy before it is possible to detect tumor response by changes in volume on conventional cross-sectional imaging modalities. The gene discussed is EGFR; the disease is neoplasm.